Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Opioid/Benzodiazepine Polydrug Abuse | ClinicalTrials.gov |
| NCT number | NCT03696017 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Wayne State University | ClinicalTrials.gov |
| Conditions | Polysubstance Abuse | ClinicalTrials.gov |
| Interventions | Multi-domain assessment battery | ClinicalTrials.gov |
| First posted | 2018-10-04 | ClinicalTrials.gov |
| Last updated | 2025-12-30 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Psychopathology | Administered once during the baseline clinical assessment. | Semi-Structured Clinical Interview for DSM (Face-to-face interview) Evaluates lifetime and current psychiatric and substance use disorders. | ClinicalTrials.gov |
| Primary | Beck Depression Inventory-II | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire measure of current depression symptoms | ClinicalTrials.gov |
| Primary | Snaith-Hamilton Pleasure Scale | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire 14-item scale that measures anhedonia, the inability to experience pleasure. The items cover the domains of: social interaction, food and drink, sensory experience, and interest/pastimes. A score of 2 or less constitutes a "normal" score, while an "abnormal" score is defined as 3 or more. Each item has four possible responses: strongly disagree, disagree, agree, or strongly agree. Either of the "disagree" responses score one point, and either of the "agree" responses score 0 points. | ClinicalTrials.gov |
| Primary | Perceived Stress Scale | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire that measures the degree to which situations in one's life are appraised as stressful. Items were designed to assess how unpredictable, uncontrollable, and overloaded respondents find their lives to be. The scale also includes a number of direct queries about current levels of experienced stress. | ClinicalTrials.gov |
| Primary | State-Trait Anxiety Inventory | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire that differentiates state anxiety from chronic trait anxiety symptoms. | ClinicalTrials.gov |
| Primary | Difficulties with Emotion Regulation Scale | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | 36-item questionnaire measure of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never \[0-10%\]") to 5 ("almost always \[91-100%\]"). Higher scores indicate more difficulty in emotion regulation. measures 6 empirically valid constructs related to emotion dysregulation: Non-acceptance of emotional responses, Difficulties in engaging in goal-directed behavior, Impulse control difficulties, Lack of emotional awareness, Limited access to emotion regulation strategies, and Lack of emotional clarity. | ClinicalTrials.gov |
| Primary | Alcohol and Drug Use Self-Efficacy Scale | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire assesses self-efficacy and responses to high-risk situations that can trigger substance use.Items are grouped into negative affect, social positive withdrawal/urges, and physical/other concerns; subjects indicate how "tempted" and "confident" they would be in each situation. | ClinicalTrials.gov |
| Primary | Distress Tolerance Scale | Administered once during the clinical assessment. | Questionnaire measure of emotional distress tolerance | ClinicalTrials.gov |
| Primary | Positive and Negative Affect Schedule-Short Form: Positive Affect | Administered once during the baseline clinical assessment. | Questionnaire: 10-item measure of Positive Affect | ClinicalTrials.gov |
| Primary | Positive and Negative Affect Schedule-Short Form: Negative Affect | Administered once during the baseline clinical assessment. | Questionnaire: 10-item measure of Negative Affect | ClinicalTrials.gov |
| Primary | Paced Auditory Serial Addition Task | Administered once during the baseline clinical assessment. | mental arithmetic task with 3 trial blocks of increasing difficulty. Subjects can escape the task during block 3; latency (sec) to task termination is a primary outcome. | ClinicalTrials.gov |
| Primary | Brief Pain Inventory-Short Form | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire measures pain severity (0=no pain; 10=pain as bad as you can imagine) and its functional impact (0=no interference; 10= interferes completely). | ClinicalTrials.gov |
| Primary | Current Opioid Misuse Measure | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire measures risk of opioid misuse | ClinicalTrials.gov |
| Primary | Insomnia Severity Index | Administered during the baseline clinical assessment, and at the 3-month follow-up visit. | Questionnaire asks about problem severity of sleep-onset, sleep-maintenance, early morning awakening, sleep satisfaction, interference with daily function, perceived impairment, and level of distress from insomnia. It has good internal consistency and concurrent validity (with polysomnography, sleep diaries, and clinician or significant-other reports), making it a valid and reliable measure of perceived sleep disturbance. | ClinicalTrials.gov |
| Primary | Epworth Sleepiness Scale | Administered once during the baseline clinical assessment. | Questionnaire measures 'sleep propensity', i.e. recent likelihood of dozing or falling asleep (rather than just feeling tired) in several situations. | ClinicalTrials.gov |
| Primary | Psychomotor Vigilance Task | Administered once during the baseline clinical assessment. | computerized, adaptive task (reaction time to a visual stimulus presented at random inter-trial intervals \[ITI\]) that will be used to assess attentional lapses; this objective, validated measure of sleepiness. | ClinicalTrials.gov |
| Primary | Go/No-Go Task | Administered once during the baseline clinical assessment. | Immediate and Delayed Memory Task assesses response inhibition. Participants are told to press a button to respond to stimulus X or Y presented in an alternating pattern (Go) and to withhold responding when the pattern is broken (No-Go). We will use percentage of correctly inhibited responses for each presentation. | ClinicalTrials.gov |
| Primary | California Verbal Learning Test-Revised | Administered once during the baseline clinical assessment. | Immediate and delayed memory will be assessed. | ClinicalTrials.gov |
| Primary | Emotional Stroop Task | Administered once during the baseline clinical assessment. | reaction time assessment of attentional bias for both emotion-related words | ClinicalTrials.gov |
| Primary | Wisconsin Card Sort Test | Administered once during the baseline clinical assessment. | number of items correct, measuring ability to shift or maintain cognitive set | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36741122 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 9
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Arithmetic Fluency Task | Primary outcome | ConductCognition |
| Emotional Stroop Task | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Immediate and Delayed Memory Task | Primary outcome | ConductCognition |
| Paced Visual Serial Addition Test | Primary outcome | ConductCognition |
| Psychomotor Vigilance Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)